fashion -WSS

fashion

author：Wikipedia 2025-10-02 11:05:53 Page View：1

Bristol Myers Squibb sign — Courtesy Bristol Myers Squibb

Bristol Myers Squibb will pay $4.1 billion for RayzeBio, the companies said Tuesday, buying into the fast-growing field of using targeted doses of radiation to treat cancer.

RayzeBio, which raised about $350 million in a September initial public offering, is working in radiopharmaceuticals, which pair the tumor-killing power of radiation with the precision of targeted cancer therapies. The company is currently running a pivotal trial of its most advanced drug, RYZ101, in neuroendocrine cancer and has a pipeline of treatments for kidney, liver, and other cancers.

Bristol Myers will pay $62.50 in cash per share of RayzeBio, a roughly 115% premium to the company’s recent trading and more than triple the company’s IPO price.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： A revolution in caring for preterm infants
Next article： Heart attack and stroke risk calculators need revising

explore

Cancer drug shortages should be causing more outrage

DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

Readout LOUD podcast: Merger Mondays, Ozempic panic

Whenisabillion-dollardealabadomen?HasWallStreetgoneoverboardonOzempic?Andhowdoyoueditachicken?Wecove

Drug repurposing or repositioning? The language matters

AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

To bolster infectious disease surveillance, genomics powerhouses team up

TuliodeOliveiraleadsSouthAfrica’sCentreforEpidemicResponseandInnovation.CourtesyCERI@SULONDON—Twores